On December 11th, 2025, the Stago Group, a global leader in diagnostics and a specialist in hemostasis, announced that it has entered into exclusive negotiations with a consortium led by ARCHIMED, an investment fund dedicated to the healthcare sector, with a view to acquiring a majority stake in the group. La Caisse (formerly Caisse de dépôt et Placement du Québec) would invest alongside ARCHIMED as a minority investor.
The transaction is expected to be finalized in the second quarter of 2026. It remains subject to the information and consultation procedure with the relevant employee representative bodies within the Stago Group, as well as prior regulatory approvals.
Rationale
This transaction would provide Stago with the necessary resources to accelerate its growth strategy, while strengthening its technological and scientific leadership. The project would build on the recognized expertise of Stago’s teams and be in line with their strategic vision, maintaining their commitments in terms of quality, customer satisfaction, and diagnostic reliability in the service of patients.
Stago at a glance
Leading player specialized in hemostasis, Stago develops and markets automated systems for blood analysis in coagulation. Headquarters are located in Paris. R&D, manufacturing and logistics activities are mainly located in Europe. Its products are available in 115 countries through a network of subsidiaries and distributors. Stago headcounts is 2,600 employees worldwide.
